Meeting
2021 ASCO Annual Meeting
Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study.
Authors
Reshma L. Mahtani
Sylvester Cancer Center, University of Miami, Deerfield Beach, FL
Reshma L. Mahtani , Alexander Niyazov , Katie Lewis , Lucy Massey , Alex Rider , Bhakti Arondekar , Michael P Lux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10598)
DOI
10.1200/JCO.2021.39.15_suppl.10598
Abstract #
10598
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Neal A. Fischbach
Poster
2024 ASCO Annual Meeting
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
First Author: Melissa Taylor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real world prevalence of biomarkers for treatment of advanced gastric cancer or gastroesophageal junction cancer in a cohort of Colombian patients.
First Author: Diego Felipe Ballen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.
First Author: Hazel Lote